Home » Newsletters » BioWorld Science

BioWorld Science

May 10, 2022

View Archived Issues

Targeting NMNAT2 confers neuroprotection in glaucoma

Hangzhou Zhongmei Huadong Pharmaceutical divulges GLP-1 receptor agonists

Universite du Luxembourg discloses new PDE6D inhibitors

Ranok Therapeutics presents new CHAMPs for cancer

Beijing Jacobio Pharmaceuticals identifies new glutaminase inhibitors

Shanghai De Novo Pharmatech synthesizes new ATR kinase inhibitors

Discovery of potent and orally bioavailable CSNK1A1 inhibitors

Clec9A-M2e construct may be a step towards a universal influenza vaccine

ANGPTL7 as a novel therapeutic target for glaucoma

TBK1 inhibition is neuroprotective in optic neuropathies

iBio presents preclinical data on monoclonal antibody candidate IBIO-101 for solid tumors

Ichnos selects trispecific antibody ISB-2001 for development in multiple myeloma

Aqilion advances program for chronic inflammatory bowel disease

Researchers develop a murine model of TEK Schlemm's canal conditional knockdown glaucoma

Comparative study focuses lens of human reproductive aging

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...